This is an old revision of the document!
Remdesivir
Remdesivir was a strange choice to see among early treatment attempts because renal failure was a known side effect, and COVID-19 has a high mortality risk multiplier for people with renal failure.1) However, Chinese researchers claimed early to have tested it in vitro on SARS-CoV-2 with promising results.
1)
Barbu et al | Sep 9, 2020 | Frontiers of Medicine | https://www.frontiersin.org/articles/10.3389/fmed.2020.567199/full